SCHEMBL25439769

SCHEMBL25439769

Cc1cc(F)c(-c2ccn3nc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)nc3c2)cc1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 3/20 0.36
CSNK2A2 P19784 2/20 0.36
ADH5 P11766 2/20 0.34
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 2/20 0.31
TSHR P16473 2/20 0.31
KMT2A Q03164 2/20 0.31
HSD17B10 Q99714 2/20 0.31
CRHBP P24387 1/20 0.31
HTT P42858 1/20 0.31
CRHR2 Q13324 1/20 0.31
USP2 O75604 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25439950 0.91 CSNK2A1 (0.38) CSNK2A1CSNK2A2KDM4EALDH1A1HSD17B10
SCHEMBL31489361 0.85 SSTR4 (0.31)
SCHEMBL25440052 0.84 CSNK2A2 (0.33) CSNK2A1CSNK2A2ADH5
SCHEMBL25440010 0.83 CSNK2A2 (0.32) CSNK2A1CSNK2A2ADH5
SCHEMBL29498023 0.83 CSNK2A2 (0.32) CSNK2A1CSNK2A2ADH5
SCHEMBL31507795 0.82 CSNK2A1 (0.32) CSNK2A1CSNK2A2
SCHEMBL29497974 0.81 ROCK2 (0.39)
SCHEMBL25440203 0.81 ROCK2 (0.39)
SCHEMBL31507676 0.81 TDP2 (0.32) CSNK2A1CSNK2A2
SCHEMBL31489293 0.80 TDP2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364737-A2 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2024-05-08 EP disclosed
EP-4229056-B1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-10 EP disclosed
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-04 US disclosed
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 CSNK2A1 500/4885CSNK2A2 544/4885ADH5 4314/4885
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors RIPK1, RIPK3, RIPK4 CSNK2A1 500/4885CSNK2A2 544/4885ADH5 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.